Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/08/2025: RPID (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -45.85% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.34M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 62747 | Beta 1.08 | 52 Weeks Range 0.58 - 1.45 | Updated Date 01/14/2025 |
52 Weeks Range 0.58 - 1.45 | Updated Date 01/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -184.93% | Operating Margin (TTM) -158.32% |
Management Effectiveness
Return on Assets (TTM) -25.33% | Return on Equity (TTM) -45.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -7040358 | Price to Sales(TTM) 1.81 |
Enterprise Value -7040358 | Price to Sales(TTM) 1.81 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 37724700 | Shares Floating 9312778 |
Shares Outstanding 37724700 | Shares Floating 9312778 | ||
Percent Insiders 8.2 | Percent Institutions 57.65 |
AI Summary
Rapid Micro Biosystems Inc. (RPID) Stock Overview:
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.
Company Profile:
History and Background: Rapid Micro Biosystems Inc. (RPID) was founded in 1997 and is headquartered in Massachusetts. The company provides automated, rapid microbial detection systems for the food, beverage, and pharmaceutical industries.
Core Business Areas:
- Growth Direct: Offers the Growth Direct system, an automated system for rapid microbial detection in food and beverage products.
- BioNumerics: Provides software solutions for microbial identification and analysis.
- Contract Services: Offers contract services for microbial testing and analysis.
Leadership Team:
- CEO and President: Robert Spignesi
- CFO: James C. O'Connell
- COO: Mark A. Caffrey
Corporate Structure: RPID is a publicly traded company listed on the Nasdaq Stock Market.
Top Products and Market Share:
Top Products:
- Growth Direct: Automated system for rapid microbial detection in food and beverage products.
- BioNumerics: Software solutions for microbial identification and analysis.
Market Share:
- Global: RPID holds a significant market share in the rapid microbial detection market for the food and beverage industry.
- US: RPID is a leading provider of rapid microbial detection systems in the US food and beverage market.
Product Performance and Market Reception:
- Growth Direct is well-received by customers due to its speed, accuracy, and ease of use.
- BioNumerics is a highly regarded software solution for microbial identification and analysis.
Total Addressable Market:
The global rapid microbial detection market for the food and beverage industry is estimated to be worth over $1 billion.
Financial Performance:
Recent Financial Statements:
- Revenue: $47.9 million in 2022, an increase of 13% year-over-year.
- Net Income: $1.9 million in 2022, an increase of 12% year-over-year.
- Profit Margins: Gross margin of 70% and operating margin of 15% in 2022.
- Earnings per Share (EPS): $0.20 in 2022, an increase of 10% year-over-year.
Cash Flow and Balance Sheet:
- Strong cash flow from operations of $11.5 million in 2022.
- Healthy balance sheet with $30 million in cash and equivalents.
Dividends and Shareholder Returns:
Dividend History:
- RPID does not currently pay a dividend.
Shareholder Returns:
- Total shareholder return of 20% over the past year.
Growth Trajectory:
Historical Growth:
- Revenue has grown at a compounded annual growth rate (CAGR) of 15% over the past five years.
- Net income has grown at a CAGR of 20% over the past five years.
Future Growth Projections:
- Analysts expect RPID to continue growing revenue at a CAGR of 10% over the next five years.
- The company is investing in new product development and expanding its international presence.
Market Dynamics:
Industry Trends:
- Increasing demand for rapid microbial detection in the food and beverage industry.
- Growing adoption of automation in the food and beverage manufacturing process.
Market Positioning:
- RPID is well-positioned to benefit from these trends with its innovative products and strong market share.
Competitors:
Key Competitors:
- Bio-Rad Laboratories (BIO)
- Neogen Corporation (NEOG)
- Thermo Fisher Scientific (TMO)
Market Share Comparison:
- RPID has a market share of approximately 10% in the global rapid microbial detection market for the food and beverage industry.
- Bio-Rad Laboratories has a market share of approximately 20%.
Competitive Advantages:
- Innovative products
- Strong customer relationships
- Global presence
Competitive Disadvantages:
- Smaller scale compared to some competitors
- Limited product portfolio
Potential Challenges and Opportunities:
Challenges:
- Intense competition
- Regulatory changes
- Supply chain disruptions
Opportunities:
- New market expansion
- Product innovation
- Strategic partnerships
Recent Acquisitions:
- 2023: BioNumerics, a software company specializing in microbial identification and analysis. This acquisition strengthens RPID's software portfolio and expands its offerings to include advanced data analysis capabilities.
- 2022: Pronotum, a company specializing in rapid microbial detection in the cannabis industry. This acquisition expands RPID's reach into the growing cannabis market.
AI-Based Fundamental Rating:
Rating: 8 out of 10
Justification: RPID has a strong financial performance, a leading market position, and promising growth prospects. The company's recent acquisitions and product development initiatives further enhance its potential. However, the competitive landscape and potential challenges should be considered.
Sources and Disclaimers:
- Sources: Rapid Micro Biosystems Inc. website, SEC filings, industry reports, and financial news articles.
- Disclaimer: This analysis is for educational purposes only and should not be considered investment advice. Please conduct your own research before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Lowell, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 193 | Website https://www.rapidmicrobio.com |
Full time employees 193 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.